Cargando…
Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)
BACKGROUND: 1. Compare SBRT +/− ADT for oligorecurrent-castration-sensitive PCa (OCS-PCa) in terms of efficacy, toxicity and Quality of Life (QoL). 2. Develop biology/imaging based prognostic tool that allows identifying OCS-PCa subclasses. METHODS: 1. Randomized clinical study (3 years for accrual...
Autores principales: | Marvaso, Giulia, Ciardo, Delia, Corrao, Giulia, Gandini, Sara, Fodor, Cristiana, Zerini, Dario, Rojas, Damaris Patricia, Augugliaro, Matteo, Bonizzi, Giuseppina, Pece, Salvatore, Cattani, Federica, Mazzocco, Ketti, Mistretta, Francesco Alessandro, Musi, Gennaro, Alessi, Sarah, Petralia, Giuseppe, Pravettoni, Gabriella, De Cobelli, Ottavio, Di Fiore, Pier Paolo, Viale, Giuseppe, Orecchia, Roberto, Jereczek-Fossa, Barbara Alicja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734417/ https://www.ncbi.nlm.nih.gov/pubmed/31500605 http://dx.doi.org/10.1186/s12885-019-6117-z |
Ejemplares similares
-
Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
por: Marvaso, Giulia, et al.
Publicado: (2021) -
Investigating Nutritional and Inflammatory Status as Predictive Biomarkers in Oligoreccurent Prostate Cancer—A RADIOSA Trial Preliminary Analysis
por: Zaffaroni, Mattia, et al.
Publicado: (2023) -
Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300
por: Marvaso, Giulia, et al.
Publicado: (2021) -
Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
por: Riva, Giulia, et al.
Publicado: (2017) -
Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRC IG 14300)
por: Russo, Stefania, et al.
Publicado: (2021)